RT Journal Article
SR Electronic
T1 Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
JF Journal of Medical Ethics
JO J Med Ethics
FD BMJ Publishing Group Ltd and Institute of Medical Ethics
SP 187
OP 189
DO 10.1136/medethics-2011-100032
VO 38
IS 3
A1 Catherine Rhodes
A1 John Harris
A1 John Sulston
A1 Catherine Spanswick
YR 2012
UL http://jme.bmj.com/content/38/3/187.abstract
AB There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future.